Table 2.
LSM estimates (cm) of SDLP and difference to placebo for daridorexant 50 and 100 mg, zopiclone, and placebo on day 2 and day 5
| Treatment | n | LSM (97.5% CI) | Difference to placebo (97.5% CI) | P value for threshold 2.6 cm |
|---|---|---|---|---|
| Day 2 | ||||
| Daridorexant 50 mg | 57 | 39.58 (37.21–41.96) | 2.19 (0.46–3.93) | 0.2991 |
| Daridorexant 100 mg | 59 | 41.82 (39.46–44.19) | 4.43 (2.72–6.15) | 0.9917 |
| Zopiclone 7.5 mg | 57 | 42.13 (39.76–44.51) | 4.75 (3.01–6.48) | 0.9972 |
| Placebo | 58 | 37.39 (35.02–39.76) | ||
| Day 5 | ||||
| Daridorexant 50 mg | 59 | 36.82 (34.58–39.06) | 0.26 (−1.08–1.59) | < 0.0001* |
| Daridorexant 100 mg | 59 | 37.50 (35.26–39.74) | 0.94 (−0.40–2.27) | 0.0027* |
| Zopiclone 7.5 mg | 56 | 38.94 (36.68–39.74) | 2.37 (1.02–3.73) | 0.3533 |
| Placebo | 58 | 36.56 (34.32–38.81) |
CI, confidence interval; LSM, least square mean; SDLP, standard deviation of the lateral position.
P values (one‐sided) are based on the mean difference of SDLP daridorexant/zopiclone treatment –placebo ≥ 2.6 cm.
*Statistically significant. Zopiclone data are included for complete display of the data.